Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > ACADEMIA
ACADEMIA
- Nat’l University Hospitals Sharing Information of Drug Purchase Prices through Central Database
May 7, 2013
- JAMS Greatly Concerned Over Diovan Paper Retractions: President Takaku
April 25, 2013
- Stivarga May Become Third/Forth-Line Colon Cancer Therapy in Japan: Prof. Sugihara
April 25, 2013
- RA Treatment Guidelines to Reflect Patients’ Values and Economic Considerations as Well as Evidence
April 24, 2013
- Osaka University Hospital to Initiate PET Microdose Study This Fall: Prof. Tomono
April 23, 2013
- New COPD Guidelines Recommend LAMA, LABA on Equal Footing
April 23, 2013
- Japan College of Rheumatology Airs Concerns over Safety of Xeljanz
April 11, 2013
- Kyoto Heart Study Chief Investigator Resigns after Diovan Paper Retractions
March 1, 2013
- Diovan Paper Contained “Careless Errors,” but “No Impact on Findings”: Chief Investigator Comments on Retraction
February 7, 2013
- JSGM Calls for 80% Generic Share, 30% Reduction in NHI Prices of Long-Listed Drugs by End of FY2017
December 6, 2012
- Less than 20% of IRBs Utilize Central IRB Despite Revised GCP Ordinance: Dr Narumoto of Okayama Univ.
December 5, 2012
- Need for Corporate Seminars May Depend on “Doctors’ Abilities”: NIRS Senior Researcher Kurihara
November 30, 2012
- AASD Scientific Meeting Shines Light on SGLT-2 Inhibitors as Next Generation Diabetes Treatment
November 28, 2012
- New Hoshi General Hospital to Give Patients Option of In-House or Legal Prescriptions Starting in January
November 22, 2012
- J-ADNI2 to Go Forward in Search of New Treatment for AD: Prof. Iwatsubo of Univ. of Tokyo
November 19, 2012
- New COPD GLs to Recommend LAMA, LABA Equally: Prof. Nagai of Tokyo Women’s Medical University
October 22, 2012
- Biosimilars Should Be Mentioned in Government Roadmap: JSGM President Muto
October 18, 2012
- Supercomputer to Dramatically Shorten Exploratory Period for Lead Compounds: Prof. Fujitani of University of Tokyo
October 16, 2012
- We Would Like to Provide iPS Cells with Medical History Identification: Prof. Yamanaka of Kyoto University
October 15, 2012
- JAOG Insists on Introduction of HPV Testing to Cervical Cancer Screening
September 14, 2012
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…